A disintegrin and metalloproteinase 17 mRNA and protein expression in esophageal squamous cell carcinoma, as well as its clinicopathological factors and prognosis

Liu,Hong‑Bin; Yang,Qi‑Chang; Shen,Yi; Zhu,Yan; Zhang,Xiao‑Juan; Chen,Hao

doi:10.3892/mmr.2014.2802

A disintegrin and metalloproteinase 17 mRNA and protein expression in esophageal squamous cell carcinoma, as well as its clinicopathological factors and prognosis

Authors:
- Hong‑Bin Liu
- Qi‑Chang Yang
- Yi Shen
- Yan Zhu
- Xiao‑Juan Zhang
- Hao Chen
View Affiliations

Affiliations: Department of Pathology, The Second Affiliated Hospital of Nantong University, Nantong, Jiangsu 226001, P.R. China
Published online on: October 29, 2014 https://doi.org/10.3892/mmr.2014.2802
Pages: 961-967
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to explore a disintegrin and metalloproteinase 17 (ADAM17) mRNA and protein expression in esophageal squamous cell carcinoma and its association with clinicopathological factors and prognosis. Through semi‑quantitative reverse transcription polymerase chain reaction, the ADAM17 mRNA expression in 50 cases of esophageal squamous cell carcinoma and corresponding normal esophageal mucosa were detected. Using streptavidin peroxidase conjugated immunohistochemistry, ADAM17 protein levels were detected in 80 cases of esophageal squamous cell carcinoma and corresponding normal esophageal mucosa. A log rank test and the Cox proportional hazards model were used for the esophageal cancer survival analysis. ADAM17 mRNA expression levels in esophageal squamous cell carcinoma and corresponding normal esophageal mucosa were 0.937±0.241 and 0.225±0.077, respectively (P<0.01). ADAM17 mRNA expression in esophageal squamous cell carcinoma was correlated with lymph node metastasis (P<0.01) and tumor, node and metastasis (TNM) staging (P<0.05), however, it was not correlated with gender, age or histological grade (P>0.05). ADAM17 protein expression rates in esophageal squamous cell carcinoma and corresponding normal esophageal mucosa were 66.25 and 6.25% respectively, a difference that was statistically significant (P<0.01). In addition, ADAM17 protein expression in esophageal squamous cells was correlated with lymph node metastasis and TNM stage (P<0.05), while it was not correlated with gender, age or histological grade (P>0.05). ADAM17 protein expression and epidermal growth factor receptor (EGFR) protein expression were positively correlated (P<0.01). Lymph node metastasis, TNM stage, ADAM17 and EGFR protein expression may be used as independent prognostic indicators of esophageal squamous cell carcinoma (all P<0.05). ADAM17 mRNA and protein were highly expressed in esophageal squamous cell carcinoma; they have important roles in invasion and metastasis and a certain value in judging the prognosis of patients with esophageal squamous cell carcinoma.

View Figures

View References

1	Klein T and Bischoff R: Active metalloproteases of the A Disintegrin and Metalloprotease (ADAM) family: biological function and structure. J Proteome Res. 10:17–33. 2011. View Article : Google Scholar
2	Benarroch EE: ADAM proteins, their ligands, and clinical implications. Neurology. 78:914–920. 2012. View Article : Google Scholar : PubMed/NCBI
3	Le Gall SM, Bobe P, Reiss K, et al: ADAMs 10 and 17 represent differentially regulated components of a general shedding machinery for membrane proteins such as transforming growth factor alpha, L-selectin, and tumor necrosis factor alpha. Mol Biol Cell. 20:1785–1794. 2009. View Article : Google Scholar : PubMed/NCBI
4	Saftig P and Reiss K: The “A Disintegrin And Metalloproteases” ADAM10 and ADAM17: novel drug targets with therapeutic potential? Eur J Cell Biol. 90:527–535. 2011. View Article : Google Scholar : PubMed/NCBI
5	Lorenzen I, Trad A and Grozinger J: Multimerisation of A disintegrin and metalloprotease protein-17 (ADAM17) is mediated by its EGF-like domain. Biochem Biophys Res Commun. 415:330–336. 2011. View Article : Google Scholar : PubMed/NCBI
6	McGowan PM, Ryan BM, Hill AD, et al: ADAM-17 expression in breast cancer correlates with variables of tumor progression. Clin Cancer Res. 13:2335–2343. 2007. View Article : Google Scholar : PubMed/NCBI
7	Baumgart A, Seidl S, Vlachou P, et al: ADAM17 regulates epidermal growth factor receptor expression through the activation of Notch1 in non-small cell lung cancer. Cancer Res. 70:5368–5378. 2010. View Article : Google Scholar : PubMed/NCBI
8	Ebi M, Kataoka H, Shimura T, et al: TGFbeta induces proHB-EGF shedding and EGFR transactivation through ADAM activation in gastric cancer cells. Biochem Biophys Res Commun. 402:449–454. 2010. View Article : Google Scholar : PubMed/NCBI
9	Ding X, Yang LY, Huang GW, Wang W and Lu WQ: ADAM17 mRNA expression in isolation, large hepatocellular carcinoma and its significance. Zhong Hua Gan Dan Wai Ke Za Zhi. 11:544–546. 2005.
10	Kornfeld JW, Meder S, Wohlberg M, et al: Overexpression of TACE and TIMP3 mRNA in head and neck cancer: association with tumour development and progression. Br J Cancer. 104:138–145. 2011. View Article : Google Scholar :
11	Hinsley EE, Hunt S, Hunter KD, Whawell SA and Lambert DW: Endothelin-1 stimulates motility of head and neck squamous carcinoma cells by promoting stromal-epithelial interactions. Int J Cancer. 130:40–47. 2012. View Article : Google Scholar
12	Sakamoto N, Oue N, Noguchi T, et al: Serial analysis of gene expression of esophageal squamous cell carcinoma: ADAMTS16 is upregulated in esophageal squamous cell carcinoma. Cancer Sci. 101:1038–1044. 2010. View Article : Google Scholar : PubMed/NCBI
13	Merchant NB, Voskresensky I, Rogers CM, et al: TACE/ADAM-17: a component of the epidermal growth factor receptor axis and a promising therapeutic target in colorectal cancer. Clin Cancer Res. 14:1182–1191. 2008. View Article : Google Scholar : PubMed/NCBI
14	Liu YP and Xu L: Influence of epidermal growth factor receptor targeted therapy related molecular detection. Zhong Hua Zhong Liu Za Zhi. 33:81–83. 2011.
15	Han Y, Xu JM, Duan HQ, et al: The treatment of EGFR gene mutation and the curative effect of treatment of advanced non-small cell lung cancer and prognosis. Zhong Hua Zhong Liu Za Zhi. 29:278–283. 2007.